Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com.
Company Details
- Employees
- 37
- Founded
- -
- Address
- 4-10 The Quadrant, Barton Lane, Abingdon,oxfordshire Ox14 3ys,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://+www.akamisbio.com
- HQ
- Abingdon, Oxfordshire
Akamis Bio Questions
Akamis Bio's website is http://+www.akamisbio.com
Akamis Bio's LinkedIn profile is https://www.linkedin.com/company/akamisbio
Akamis Bio has
37 employees.
View email and phone details for 37
employees at Akamis Bio.
Akamis Bio's industry is
Biotechnology Research
Akamis Bio's top competitors are
Adaptimmune,
Indapta Therapeutics,
Enara Bio,
Oxb,
Accession Therapeutics Limited,
Barinthus Biotherapeutics,
Immunocore,
Theolytics,
Greywolf Therapeutics,
Replimune.
Akamis Bio's categories are Biotechnology Research
Akamis Bio's founding year is 2010
